

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number
WO 02/11756 A2

(51) International Patent Classification⁷: **A61K 39/00**,
C07K 14/445, C12N 15/12, 15/63, C07K 16/20, A61P
33/02

(21) International Application Number: PCT/US01/24725

(22) International Filing Date: 7 August 2001 (07.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/223,525 7 August 2000 (07.08.2000) US

(71) Applicant (for all designated States except US): **EN-
TREMED, INC.** [US/US]; 9640 Medical Center Drive,
Suite 200, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **NARUM, David, L.**
[US/US]; 8533 Fountain Valley Drive, Gaithersburg, MD
20879 (US). **SIM, Kim, L.** [US/US]; 308 Argosy Drive,
Gaithersburg, MD 20878 (US).

(74) Agents: **SHOPE, Suzanne, S.** et al.; Kilpatrick Stockton
LLP, Suite 2800, 1100 Peachtree Street, Atlanta, GA 30309
(US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.


(84) Designated States (regional):¹ ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ANTI-PLASMODIUM COMPOSITIONS AND METHODS OF USE



(57) Abstract: Compositions that inhibit the binding of Plasmodium falciparum to erythrocytes include a family of erythrocyte binding proteins (EBPs). The EBPs are paralogues of the P. falciparum binding protein EBA-175. The present invention includes peptides of the paralogues that prevent the binding of P. falciparum. Antibodies specific for each paralogue that also prevent the binding of P. falciparum are also included. Methods of the invention utilize the paralogues, antibodies thereof and peptide compositions for the diagnosis, prevention, and treatment of P. falciparum diseases such as malaria, as well as methods for the detection of P. falciparum in biological samples and culture media.

5

10

ANTI-PLASMODIUM COMPOSITIONS AND METHODS OF USE

15

FIELD OF THE INVENTION

The present invention relates to the fields of microbiology and immunology and more specifically relates to compositions and methods for the detection, diagnosis, prevention and treatment of malaria. In particular, the invention pertains to a family of paralogues of EBA-175, antibodies specific to each paralogue, peptides of the paralogues and peptides of the antibodies that inhibit the binding of *Plasmodium falciparum* erythrocyte binding protein antigens to erythrocytes.

25

BACKGROUND OF THE INVENTION

Although endemic malaria has disappeared from the United States, malaria continues to be one of the most important infectious diseases in the world as it kills millions of people each year in countries throughout Africa, Asia and Latin America. The characteristic presentation of malaria is chills followed by a fever ranging from 104-107°F, followed by profuse sweating. Other manifestations of malaria include anemia, decreased blood flow to vital organs, thrombocytopenia, and glomerulonephritis. Additionally, when the central nervous system is involved, symptoms include delirium, convulsions, paralysis, coma, and even rapid death.

35

Malarial diseases in humans are caused by four species of the *Plasmodium* parasite: *Plasmodium falciparum* (Pf), *Plasmodium vivax* (Pm), *Plasmodium ovali* (Po), and *Plasmodium malariae* (Pm). Each of these species is transmitted to the human via a female *Anopheles* mosquito that transmits *Plasmodium* parasites, or sporozoites. Once the sporozoites enter the bloodstream of the human, they localize in liver cells, or hepatocytes. One to two weeks later, the infected hepatocytes rupture and release mature parasites, or merozoites. The merozoites then begin the erythrocytic phase of malaria by attaching to and invading red blood cells, or erythrocytes.

The invasion of the erythrocytes by the malarial parasites is the direct cause of malarial pathogenesis and pathology. The fever, anemia, circulatory changes, and immunopathologic phenomena characteristic of malaria are largely the result of red cell rupture and the host's immune response to parasitized erythrocytes. For these reasons, the erythrocytic stage of the *Plasmodium* life cycle is of vital importance to vaccine development and treatment of malaria.

There are a number of strategies for developing new or novel therapeutics for the erythrocytic stage of malaria. One strategy is to identify parasitic molecules that are critical to the survival of the parasite. Extracellular merozoites released from infected hepatocytes or from infected erythrocytes must invade other erythrocytes within minutes if they are to survive. Invasion by the malaria parasite is dependent upon the binding of parasite proteins to receptors on the erythrocyte surface (Hadley *et al.*, 1986).

Interestingly, different parasite species use different erythrocytic receptors for invasion of erythrocytes. *P. falciparum* invades erythrocytes through a 175 kDa erythrocyte binding protein called EBA-175. The gene encoding EBA-175 of Pf has been cloned and sequenced (Sim *et al.*, 1990; Fang *et al.*, 1991). EBA-175 functions as an erythrocyte invasion ligand that binds to its receptor, glycophorin A, on erythrocytes during invasion (Camus and Hadley, 1985; Sim *et al.*, 1990; Orlandi *et al.*, 1992; Sim *et al.*, 1994b). In contrast, the human *P. vivax*

and the simian *P. knowlesi* invade erythrocytes by binding Duffy blood group antigens present on some erythrocytes (Miller *et al.*, 1975). The genes encoding the Duffy antigen binding proteins of *P. vivax* and *P. knowlesi* have been cloned and sequenced (Fang *et al.*, 1991 and Adams *et al.*, 1990, respectively).

Sequencing of the genes encoding the proteins used by *P. vivax* and *P. knowlesi* for erythrocyte invasion demonstrated that these proteins are members of the same gene family as the genes that encode the EBA-175, the protein used by *P. falciparum* for erythrocyte invasion (Adams *et al.*, 1992). Homology between the Duffy binding proteins and EBA-175 is restricted to 5' and 3' cysteine rich domains. Within these cysteine rich domains, the cysteines and some aromatic residues are conserved, but the intervening amino acid sequences differ. Sim *et al.* (1994b) demonstrated that the 5' cysteine rich domain of EBA-175 of *P. falciparum* contains the receptor binding domain, while Chitnis and Miller (1994) demonstrated that the 5' cysteine rich region of *P. vivax* and *P. knowlesi* contain the Duffy binding domain. See Figure 1.

What is needed for erythrocytic malaria vaccine development is the identification and targeting of parasite molecules involved in the process of erythrocyte invasion. Blockade of this ligand-receptor-mediated event can inhibit parasite development *in vitro*.

Invasion of erythrocytes by malaria parasites results from merozoite ligands interacting with erythrocyte receptors. Within *Plasmodium* a family of merozoite ligands (orthologues) that are erythrocyte-binding proteins (EBPs) has been identified. In the most severe human malaria, *Plasmodium falciparum*, the EBP is identified as the erythrocyte binding protein-175 (or EBA-175), and in *P. vivax*, the second most prevalent human malaria and the simian malaria *P. knowlesi*, the EBPs are termed the Duffy antigen binding proteins (PvDABP or PkDABP, respectively). Analysis of the deduced amino sequence of these orthologous proteins (EBA-175, PvDABP and PkDABP) lead to the classification of seven distinct domains encoding regions of greater or lesser similarity (Adams *et al.* 1992). Within the molecular family, two

regions show significant levels of conservation, these are identified as region II (RII), which encodes for the ligand-binding domain and region VI (RVI), which has as yet an unknown function. EBA-175 RII binds sialic acid residues in conjunction with the peptide backbone of glycophorin A. PvDABP and PkDABP RII bind the Duffy blood group antigens, which are chemokine receptors (Horuk *et al.* 1993). PvDABP and PkDABP have a single cysteine rich domain (termed F1) while EBA-175 RII contains essentially a duplicate of F1, termed F1 and F2. Both RII and RVI domains contain cysteine rich motifs. One function of RII and RVI is apparently to provide for a conserved tertiary structure, critical for the ligand-receptor interaction that leads to erythrocyte invasion. Erythrocytic invasion by *P. vivax* merozoites appears dependent on the Duffy blood group antigens while in vitro studies have shown that *P. falciparum* may use alternative invasive pathways (Narum *et al.* 2000, Dolan *et al.* 1994).

SUMMARY OF THE INVENTION

The present invention provides compositions and methods for detecting, diagnosing, preventing and treating *Plasmodium falciparum* and *Plasmodium falciparum* related infections. In particular, the compositions include a family of merozoite ligands that are erythrocyte binding proteins (EBPs). The EBPs of the invention are paralogues of EBA-175, an EBP in *P. falciparum*. The invention further comprises antibodies specific to each paralogue, peptides of the paralogues, and peptides of the antibodies that specifically inhibit binding of *P. falciparum* erythrocyte binding proteins to erythrocytes.

The cysteine residues of the EBPs are conserved within the erythrocyte binding domain of EBA-175 RII. Some of the family members of the present invention include EBP2 (SEQ ID NO:1), EBP3 (SEQ ID NO:2), EBP4 (SEQ ID NO:3), and EBP5 (SEQ ID NO:4).

More specifically, the paralogues and respective peptides of the invention are useful as potential vaccine candidates, targets for producing antibodies, targets for small blocking peptides, and diagnostics.

The compositions also include *P. falciparum* antibodies to the family of EBA-175 paralogues and antibody fragments thereto, *P. falciparum* blocking peptides derived from the paralogues and/or antibodies thereto, *P. falciparum* antisera, *P. falciparum* receptor agonists and *P. falciparum* receptor antagonists linked to cytotoxic agents. Such compositions are also useful for research applications, as vaccine candidates, as blocking peptides, diagnostics and prognostics. The compositions, when combined with pharmaceutically acceptable excipients, or sustained-release compounds or compositions, such as biodegradable polymers, are useful as therapeutic agents such as vaccine or treatment compositions.

Diagnostic and analytical methods and kits may be developed for detection and measurement of *P. falciparum* in a variety of biological samples including biological fluids and biological tissues, and for localization of *P. falciparum* in tissues and cells. The method and kit can be in any configuration well known to those of ordinary skill in the art.

The methods of the present invention include methods of treating, diagnosing and preventing *P. falciparum* diseases such as malaria. These methods employ the family of paralogues of the EBA-175 protein, the antibodies specific for individual paralogues and the blocking peptides described herein. Methods of prevention may include passive immunization prior to infection by *Plasmodium falciparum* parasites to inhibit parasitic infection of erythrocytes. Methods of treatment may also include administration after infection to inhibit the spread of the parasite and ameliorate the symptoms of *P. falciparum* infection. Methods of diagnosis of *P. falciparum* infection include methods directed toward combining a biological sample with the paralogues and/or antibodies described herein, wherein the binding of the paralogues and/or antibodies indicates malaria. Methods of detection of *P. falciparum* and *P. falciparum* erythrocyte binding proteins include methods directed toward the detection of *P. falciparum* and *P. falciparum* erythrocyte binding

proteins or antibodies thereto in biological samples such as biological fluids, tissues and in culture media.

Also provided are methods of detecting additional family members of the paralogues of *P. falciparum* and *P. falciparum* erythrocyte binding proteins. Criteria include the identification of regions within malaria proteins that likely share a molecular structure that function as a receptor binding domain as identified by homology between EBP region II (F1 and/or F2) and/or region VI. The ligand binding region of interest is primarily the disulfide forming amino acid cysteine rich region which also includes other aromatic amino acids such as proline and tryptophan.

Accordingly, it is an object of the present invention to provide compositions comprising one or more paralogues of *P. falciparum* erythrocyte binding protein, antibodies specific for each paralogue or blocking peptides derived from the paralogues or antibodies.

It is another object of the present invention to provide a method for the treatment of *P. falciparum* related diseases such as malaria.

It is a further object of the present invention to provide a method for the treatment of malaria, wherein compositions comprising one or more paralogues of *P. falciparum* erythrocyte binding protein, antibodies specific for each paralogue and/or blocking peptides derived from the paralogues or antibodies are administered to an individual in need of such treatment.

It is another object of the present invention to provide a method for the diagnosis of *P. falciparum* related diseases such as malaria.

It is yet another object of the present invention to provide a method for the diagnosis of malaria, wherein compositions comprising one or more paralogues of *P. falciparum* erythrocyte binding protein, and/or antibodies specific for each paralogue are used.

A further object of the present invention is to provide a method for the prevention of *P. falciparum* related diseases such as malaria.

5 It is another object of the present invention to provide a method for the prevention of malaria, wherein compositions comprising one or more paralogues or regions thereof of *P. falciparum* erythrocyte binding protein, antibodies specific for each paralogue and/or blocking peptides derived from the paralogues or antibodies are administered to an individual in need of such prevention.

10 Another object of the present invention to provide a method of detection of *P. falciparum* in culture media and in biological samples such as biological tissues and fluids.

15 It is a further object of the present invention to provide a method of detection of *P. falciparum*, wherein compositions comprising one or more paralogues of *P. falciparum* erythrocyte binding protein and/or antibodies specific for each paralogue are used.

20 These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments and the appended claims.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1: *Gene Structure of Plasmodium Erythrocyte Binding Proteins*

25 Region I of EBA-175 encompasses amino acid residues 20-157, region II amino acids 145-760, region III-V amino acids 743-1322 and region VI amino acids 1304-1394. Region II is further subdivided into regions F1 and F2.

30 Figure 2: *Nucleotide and deduced amino acid sequence alignment of five EBA-175 Blocking Peptides*

Nucleotide and deduced amino acid sequence alignment of partial ORF of *eba-175 (ebp1)*, *ebp2*, *ebp3*, *ebp4* and *ebp5*. Identical amino acid residues are shown in boxes.

Figure 3: *EBP2 specific polyclonal antibodies blocked EBP2 binding to human erythrocytes*

The blocking of binding of processed fragments of EBP2 with erythrocytes as a percent compared to the control which was determined at a 1/10 dilution. Equal volumes of erythrocyte lysate were immunoprecipitated with EBP2 specific polyclonal antibodies.

DETAILED DESCRIPTION

Compositions and methods for preventing and treating *P. falciparum* infection, diagnosing diseases related to *P. falciparum* infection, and preventing diseases related to *P. falciparum* infection are provided. The compositions include at least one of a family of paralogues, antibodies specific for each paralogue and peptides derived from the paralogues and antibodies that specifically inhibit binding of *P. falciparum* erythrocyte binding proteins and fragments thereof. The paralogues, antibodies and fragments thereof are useful in malaria vaccines and for receptor blocking therapies.

More specifically, a family of paralogues to the EBA-175 erythrocyte binding protein (EBP) has been identified in *P. falciparum*. The cysteine residues of the EBPs are conserved within the erythrocyte binding domain of EBA-175 RII. The RII region was previously disclosed in U.S. Provisional Patent Application Nos. 60/122,842, 60/153,575, PCT/US00/05820, and U.S. Pat. Nos. 5,993,827 and 5,849,306 to Sim *et al.*, each of which is herein incorporated by reference. Examples of the family members of the present invention are shown in Fig. 2 and include EBP2 (SEQ ID NO:1), EBP3 (SEQ ID NO:2), EBP4 (SEQ ID NO:3), and EBP5 (SEQ ID NO:4). Fig. 2 is an alignment report of EBP1_5 070500.MEG, using Clustal method with PAM250 residue weight table.

Characteristics of the family members include conservation of the cysteine rich domains identified as RII (F1 and/or F2), and/or RVI described herein. Members of this family are chosen by the

identification of either of these regions independently or as a protein that contains both regions. Molecules with only a RII binding domain may act as an EBP and be subject to antibody mediated blockade by a vaccine or blocking therapy formulation.

5 Also included in the present invention are nucleotide sequences that encode each of the paralogs of *P. falciparum* erythrocyte binding protein described herein. The compositions further include vectors containing a DNA sequence encoding at least one of the
10 paralogues of *P. falciparum*, fragments thereof, or blocking peptides, wherein the vectors are capable of expressing *P. falciparum* paralogs, fragments thereof, or blocking peptides when present in a cell. Cells containing the vectors are also included as compositions, wherein the vectors contain a DNA sequence encoding at least one of the paralogs
15 of *P. falciparum*, fragments thereof, or blocking peptides, and wherein the vectors are capable of expressing at least one of the paralogs of *P. falciparum*, fragments thereof, or blocking peptides, when present in the cell.

 The family of paralogs of the *P. falciparum* erythrocyte binding protein (EBP) and the blocking peptides described herein are
20 useful *in vitro* as research tools for studying *P. falciparum* in general and *P. falciparum* related diseases such as malaria. The family of paralogs of *P. falciparum* EBA-175 are also useful as diagnostic reagents in the immunoassays described herein.

 Additionally, the paralogs of EBA-175 and blocking
25 peptides of the present invention are useful for the production of vaccines and therapeutic compositions. Pharmaceutical compositions containing a member of the paralogs family and/or peptides such as vaccines and therapeutic formulations are provided. The methods described herein are methods for detection, diagnosis, prevention and treatment of *P.*
30 *falciparum* mediated malarial infections. Assays for the detection or quantitation of *P. falciparum* antigens may employ antigens derived from a biological sample such as a biological fluid or tissue or from culture media.

Additionally, antibodies specific for each of the paralogues are provided for in this invention. The compositions and uses disclosed above for the paralogues may include the antibodies and fragments thereof in place of, or in addition to, the paralogues.

5 The terms "a", "an" and "the" as used herein are defined to mean "one or more" and include the plural unless the context is inappropriate.

 The terms "polypeptide", "peptide", and "protein", as used herein, are interchangeable and are defined to mean a biomolecule
10 composed of two or more amino acids linked by a peptide bond.

 The term "antigen" refers to an entity or fragment thereof which can induce an immune response in a mammal. The term includes immunogens and regions responsible for antigenicity or antigenic determinants. "Antigenic determinant" refers to a region of a *P. falciparum* protein recognized by an antibody.
15

 As used herein, the terms "detecting" or "detection" refer to quantitatively or quantitatively determining the presence of the biomolecule under investigation.

 By "isolated" is meant a biological molecule free from at
20 least some of the components with which it naturally occurs.

 The terms "antibody" and "antibodies" as used herein include monoclonal antibodies, polyclonal, chimeric, single chain, bispecific, simianized, and humanized antibodies, Fab fragments, including the products of an Fab immunoglobulin expression library, and
25 peptide antibody fragments.

 The phrases "specific for", "specifically binds to", "specifically hybridizes to" and "specifically immunoreactive with", when referring to an antibody or blocking peptide, refer to a binding reaction which is determinative of the presence of a peptide or antibody in the
30 presence of a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies and blocking peptides bind preferentially to a particular peptide or antibody and do not bind in a significant amount to other proteins present

in the sample. Specific binding to a peptide or antibody under such conditions requires an antibody or blocking peptide that is selected for its specificity for a particular protein. A variety of immunoassay formats may be used to select antibodies and peptides specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. *See, Harlow and Lane (1988) Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity.

As used herein, the term "paralogue" includes different genes in the same species which are so similar in nucleotide sequence or amino acid sequence or functional regions contained within conserved regions of each molecule that they are assumed to have originated from a single ancestral gene.

As used herein, the term "vaccine" includes compositions comprising the paralogues of the invention, blocking or neutralizing antibodies, or fragments thereof, or blocking peptides or fragments of the paralogues, used for passive immunization of individuals prior to or following infection by *P. falciparum*. Vaccines are known in the art and are used to stimulate immune response in the body by creating antibodies or activated T lymphocytes capable of controlling the infecting organism. The result is protection against a disease with the duration of the protection depending on the particular vaccine. The immune system produces antibodies and memory cells for pathogens so that subsequent exposure does not result in disease. A successful vaccine does the same thing, usually without risk of illness.

Vaccines can comprise four general classes: those containing infectious agents killed by physical or chemical means; those containing living attenuated infectious organisms; those containing soluble toxins or microorganisms; and those containing substances extracted from the infectious agents. Means of administering vaccines include, but are not limited to, orally or parenterally by injection,

preferably by subcutaneous or intramuscular injection. Preparation and administration of oral vaccines are disclosed in U.S. Patent No. 6,103,243, incorporated herein by reference.

5 The terms "blocking antibodies" or "neutralizing antibodies" refer to antibodies that bind specifically to *P. falciparum* antigens. The term "blocking peptides" refers to peptides that specifically inhibit the binding of *P. falciparum* to an erythrocyte. More particularly, the term "blocking peptides" refers to peptides that specifically inhibit the binding of an EBA-175 erythrocyte binding protein to an erythrocyte.

10 The compositions of the present invention include at least one member of a family of paralogues to *P. falciparum* erythrocytic binding protein EBA-175. *P. falciparum* erythrocytic binding proteins are *P. falciparum* derived proteins that bind to residues or proteins present on erythrocytes and facilitate *P. falciparum* invasion of erythrocytes.

15 The compositions of the present invention also include portions of the paralogues for use as blocking peptides that specifically inhibit binding of *P. falciparum* erythrocytic binding proteins to erythrocytes. In another preferred embodiment, the blocking peptides have a length within the range of 5-15 amino acids. Preferably, the length
20 is within the range of 9-11 amino acids. In an alternate embodiment, there is a cysteine residue cap on each end of the blocking peptide. When creating the blocking peptides of the present invention, it is to be noted that the peptides may optionally comprise a carboxy-terminal amino acid sequence of GGGS (SEQ ID NO:5) as is well known in phage display
25 techniques.

A preferred embodiment of the invention is the EBP2
paralogue of *P. falciparum* EBA-175. The EBP2 paralogue has a partial open reading frame (ORF) of a gene that shared the conserved cysteine rich motif of the EBP family and especially of EBA-175 RII (F1 and F2)
30 although the overall amino acid identity was less than 25% (shown in Figure 2).

The ORF of the EBP2 gene sequence was compared to the *P. falciparum* 3D7 strain EBA-175 region I to VI. The overall level of

amino acid identity was 24.7% by the Lipman-Pearson Method of analysis. A comparison of EBA-175 region II, identified as the ligand-receptor binding domain for its receptor glycophorin A, demonstrated almost complete conservation of the cysteine residues (26 out of 27).
5 Comparison of RII alone by the Lipman-Pearson Method of analysis showed 37.9% level of conservation when identical amino acids and conserved substitutions were included. EBA-175 RII contains two domains that have similar cysteine motifs (F1 and F2). EBP2 has a similar structural arrangement, identified here as F1 and F2. The unique
10 deletion of a cysteine residue was found in F1 (Fig. 2). Other structural amino acids, proline (6 out of 12) and tryptophan (13 out of 13) were also conserved. Another conserved region identified earlier within EBA-175 and DABP (Adams *et al.*, 1992 PNAS), with an unknown function, is RVI. Comparison of the EBP2 RVI and EBA-175 RVI deduced amino
15 sequence showed that the cysteine residues were completely conserved (8 out of 8). The level of amino acid conservation (identity and conserved substitutions) was 41.6% by the same analysis as described above.

The gene *ebp2* is apparently located on chromosome 13. The ORF of the *ebp2* gene encodes for two regions that are conserved
20 between *P. falciparum*, *P. vivax* and *P. knowlesi* (Adams *et al.*, 1992). The first region identified as the ligand-binding domain is RII and the second region that has as yet an unknown function is RVI (Fig. 2). A comparison between EBP2 and EBA-175 showed that EBP2 has little homology with the regions III to V defined for EBA-175. The ORF of
25 the partial gene sequence encoding *ebp2* does not include the membrane-spanning domain nor the cytoplasmic tail described for EBA-175. The ORF of the partial gene sequence of *ebp2* encoded for a molecule of approximately 133 kDa. The molecular mass of EBP2 identified by immunoprecipitation was 130 kDa (Example 5), which suggests that
30 nearly the entire gene sequence has been identified. Subcellular localization studies by IFA demonstrated that EBP2 colocalized with EBA-175 at the apical end of the merozoite. EBA-175 is trafficked to the

micronemes, which are organelles localized at the merozoites apical end and are involved in parasite invasion (Sim *et al.*, 1992).

5 An orthologue of EBA-175 present in *P. vivax*, that is identified as the Duffy-antigen binding protein is most similar to EBP2-F1. A comparison of EBP2 and the *P. vivax* DABP region II deduced amino acid sequence showed that DABP region II is more similar to EBP2-F1 (12 out of 13 cysteines are conserved) which is similar to that previously reported for EBA-175 RII-F1 (Adams *et al.*, 1992).

10 Parasite invasion of erythrocytes is known to occur by different invasion pathways *in vitro*. Analysis of *P. falciparum* strains adapted to long-term *in vitro* culture (Narum *et al.*, 2000, Dolan *et al.*, 1994) has shown that different parasites strains may invade erythrocytes in a sialic acid dependent and sialic acid independent manner. This is generally determined by enzymatically treating erythrocytes with neuraminidase, which cleaves sialic acid residues. It is known that EBA-175 binds sialic acid residues in conjunction with the peptide backbone of glycophorin A (Sim *et al.*, 1994). EBP2 erythrocyte binding was also dependent on sialic acid residues for binding (Example 6). The binding affinity of EBP2 appears greater than EBA-175 since EBP2 was not removed by 150 mM NaCl wash (Example 5). The existence of a family of EBPs broadens the spectrum of phenotypic differences between erythrocytes that that may be utilized by *P. falciparum*.

25 In summary, EBP2 is a novel *P. falciparum* 130 kDa EBP belonging to a family of paralogues of EBA-175. EBP2 also has a ligand-binding domain, identified as RII. EBP2 is localized within the merozoite apex and native protein binds erythrocytes in a sialic acid dependent manner. EBP2 is a malaria vaccine candidate and target for a receptor blocking therapy.

30 Also provided herein are antibodies to each of the paralogues. In a preferred embodiment of the present invention, the antibodies are specific for each of the paralogues of the *P. falciparum* binding proteins. In a further preferred embodiment, the antibodies are monoclonal and directed toward paralogues of the erythrocyte binding

protein EBA-175 as defined by Camus and Hadley (1985), Sim *et al.* (1990), and Orlandi *et al.* (1992).

In another preferred embodiment EBP2 RII specific antibodies that did not cross-react with native EBA-175 were generated using a DNA vaccine. These antibodies recognize a novel 130 kDa protein that bound human erythrocytes in a sialic acid dependent manner. EBP2 RII specific antibodies blocked native EBP2 binding in a concentration dependent manner, which indicated that EBP2 RII was the ligand binding domain.

The inventors have studied whether certain EBA-175 RII paralogues that block EBA-175 binding will inhibit merozoite invasion *in vitro*. The inventors have also studied whether certain antibodies specific to EBA-175 paralogues have a similar blocking effect on merozoite invasion. It was found that EBP2 RII specific antibodies blocked EBP2 binding to erythrocytes. EBA-175 RII antibody titers correlate with control of parasitemia in an EBA-175 RII Aotus monkey challenge study. Therefore, EBP2 antibodies for inhibition of parasite development *in vitro* are claimed herein.

The antibodies of the present invention can be polyclonal antibodies or monoclonal antibodies. Antibodies specific for the family of paralogues of *P. falciparum* erythrocyte binding proteins may be administered to a human or animal to passively immunize the human or animal against *P. falciparum* infection, thereby reducing *P. falciparum* related diseases such as malaria. Antibody derived blocking peptides specific for *P. falciparum* erythrocyte binding proteins may be administered to a human or animal to immunize the human or animal against *P. falciparum* infection, thereby reducing *P. falciparum* related diseases such as malaria. The antibodies are also useful as *in vitro* research tools for studying malaria and for isolating large quantities of *P. falciparum* erythrocyte binding proteins. The antibodies specific for the family of paralogues of *P. falciparum* erythrocyte binding proteins can be used in diagnostic kits to detect the presence and quantity of *P. falciparum* erythrocyte binding proteins, which is diagnostic or prognostic

for the occurrence or recurrence of diseases such as malaria. Additionally, the antibody derived blocking peptides that inhibit binding of *P. falciparum* binding to erythrocytes can be used in diagnostic kits to detect the presence and quantity of *P. falciparum* antibodies, which is diagnostic or prognostic for the occurrence of diseases such as malaria.

When labeled isotopically or with other molecules or proteins, the *P. falciparum* antibodies to the family of EBA-175 paralogues are useful in the identification and quantitation of *P. falciparum* utilizing techniques including, but not limited to, positron emission tomography, autoradiography, flow cytometry, radioreceptor binding assays, and immunohistochemistry.

The antibodies and antibody derived blocking peptides of each of the paralogues of the present invention can be isolated from serum or synthesized by chemical or biological methods. For example, the antibodies and antibody derived blocking peptides can be isolated from cell culture, produced by recombinant gene expression or polypeptide synthesis, or derived by *in vitro* enzymatic catalysis of larger, encompassing polypeptides to yield blocking or neutralizing antibodies or antibody derived blocking peptides. Recombinant techniques include gene amplification from DNA sources using amplification techniques such as the polymerase chain reaction (PCR), and gene amplification from RNA sources using amplification techniques such as reverse transcriptase/PCR. In a preferred embodiment, the antibody derived blocking peptides are produced and analyzed via phage display technology. Phage vectors that may be used in phage display technology include, but are not limited to, λ , M13, MS2, Mu, P4, λ gtII, and ϕ X174.

The antibodies and antibody derived blocking peptides of the present invention may be labeled directly with a detectable label for identification and quantitation of *P. falciparum* or antibody thereto. Labels for use in immunoassays are generally known to those skilled in the art and include enzymes, radioisotopes, and fluorescent, luminescent and chromogenic substances including colored particles such as colloidal

gold and latex beads. Suitable immunoassays include enzyme-linked immunosorbent assays (ELISA) and radioimmunoassays.

Alternatively, the antibodies and antibody derived blocking peptides of the present invention may be labeled indirectly by reaction with labeled substances that have an affinity for immunoglobulin, such as protein A or G or second antibodies. When using secondary antibodies, a suitable immunoassay is an immunoblot or Western blot. Additionally, the antibodies or antibody derived blocking peptides may be conjugated with a second substance and detected with a labeled third substance having an affinity for the second substance conjugated to the antibody. For example, the antibodies or antibody derived blocking peptides may be conjugated to biotin and the antibody-biotin conjugate detected using labeled avidin or streptavidin. Similarly, the antibodies or antibody derived blocking peptides may be conjugated to a hapten and the antibody-hapten conjugate detected using labeled anti-hapten antibody. These and other methods of labeling antibodies and assay conjugates are well known to those skilled in the art.

When labeled with a detectable biomolecule or chemical, the *P. falciparum* erythrocyte binding protein antibodies and antibody derived blocking peptides described above are useful for purposes such as *in vivo* and *in vitro* diagnostics and laboratory research using the methods and assays described below. Various types of labels and methods of conjugating the labels to the polypeptides and antibodies are well known to those skilled in the art. Several specific labels are set forth below.

For example, the antibodies and antibody derived blocking peptides are conjugated to a radiolabel such as, but not restricted to, ^{32}P , ^3H , ^{14}C , ^{35}S , ^{125}I , or ^{131}I . Detection of a label can be by methods such as scintillation counting, gamma ray spectrometry or autoradiography.

Bioluminescent labels, such as derivatives of firefly luciferin, are also useful. The bioluminescent substance is covalently bound to the polypeptide or antibody by conventional methods, and the labeled antibody is detected when an enzyme, such as luciferase, catalyzes

a reaction with ATP causing the bioluminescent molecule to emit photons of light.

Fluorogens may also be used as labels. Examples of fluorogens include fluorescein and derivatives, phycoerythrin, allo-phycoerythrin, phycocyanin, rhodamine, and Texas Red. The fluorogens are generally detected by a fluorescence detector.

The antibodies and antibody derived peptides can alternatively be labeled with a chromogen to provide an enzyme or affinity label. For example, the antibody can be biotinylated so that it can be utilized in a biotin-avidin reaction, which may also be coupled to a label such as an enzyme or fluorogen. Alternatively, the antibodies or antibody derived peptides can be labeled with peroxidase, alkaline phosphatase or other enzymes giving a chromogenic or fluorogenic reaction upon addition of substrate. Additives such as 5-amino-2,3-dihydro-1,4-phthalazinedione (also known as LuminolTM) (Sigma Chemical Company, St. Louis, MO) and rate enhancers such as p-hydroxybiphenyl (also known as p-phenylphenol) (Sigma Chemical Company, St. Louis, MO) can be used to amplify enzymes such as horseradish peroxidase through a luminescent reaction; and luminogenic or fluorogenic dioxetane derivatives of enzyme substrates can also be used. Such labels can be detected using enzyme-linked immunoassays (ELISA) or by detecting a color change with the aid of a spectrophotometer. In addition, antibodies and antibody derived peptides may be labeled with colloidal gold for use in immunoelectron microscopy in accordance with methods well known to those skilled in the art.

The paralogues, antibodies and derived blocking peptides described herein are particularly useful for the treatment, prevention, diagnosis and detection of *P. falciparum* infections. The paralogues, antibodies and derived blocking peptides of the present invention may be used for the treatment, prevention, diagnosis or prognosis of *P. falciparum* related diseases such as malaria. Methods of prevention include passive immunization with the paralogues and/or antibodies of the present invention prior to infection by *P. falciparum* to inhibit parasitic

infection of erythrocytes. Methods of prevention also include active immunization with the derived blocking peptides of the present invention prior to infection by *P. falciparum* to inhibit parasitic infection of erythrocytes. Methods of treatment include administration of the paralogues, antibodies and/or derived blocking peptides after infection to inhibit the spread of the parasite and ameliorate the symptoms of *P. falciparum* infection. The paralogues, antibodies and derived peptides of the present invention may also be used to detect or quantify *P. falciparum* in a biological sample or specimen or culture media, or used in diagnostic methods and kits, as described below. Results from these tests can be used to predict or diagnose the occurrence or recurrence of *P. falciparum* mediated diseases such as malaria. Paralogues, antibodies and derived peptides of the invention may also be used in production facilities or laboratories to isolate additional quantities of the *P. falciparum* erythrocytic binding proteins and/or paralogues thereof, such as by affinity chromatography, or for the development of peptide agonists or antagonists.

Plasmodium falciparum related diseases such as malaria are prevented or treated by administering to a patient suffering from a *P. falciparum* related disease, a pharmaceutical composition containing substantially purified *P. falciparum* erythrocyte binding protein paralogues, peptides thereof and antibodies thereof, *P. falciparum* antibody derived blocking peptides, *P. falciparum* polypeptide agonists or antagonists, or *P. falciparum* polypeptide antisera. Additional prevention and treatment methods include administration of *P. falciparum* erythrocyte binding protein paralogues, peptides thereof and antibodies thereof, *P. falciparum* antibody derived blocking peptides, *P. falciparum* polypeptide antisera, or *P. falciparum* polypeptide receptor agonists and antagonists linked to cytotoxic or anti-parasitic agents.

The paralogues and antibodies specific thereof may be administered to a patient to passively immunize the patient against *P. falciparum* infection, thereby reducing *P. falciparum* related diseases such as malaria. The derived blocking peptides that specifically inhibit binding

of *P. falciparum* to a red blood cell may also be administered to a patient to actively immunize the patient against *P. falciparum* infection, thereby reducing *P. falciparum* related diseases such as malaria. Administration of the *P. falciparum* erythrocyte binding protein paralogues, antibodies or derived blocking peptides may occur prior to any signs of *P. falciparum* infection. Such an administration would be important in individuals in areas where *P. falciparum* is endemic, or to individuals planning to travel to endemic areas. Administration of the *P. falciparum* erythrocyte binding protein paralogues, antibodies and derived blocking peptides may also occur after signs of *P. falciparum* infection have surfaced in order to interrupt the life cycle of the *Plasmodium* parasite and inhibit the spread of the organism.

In a preferred embodiment, a vaccine for passive or active immunization against malaria is packaged in a single dosage for immunization by parenteral (i.e., intramuscular, intradermal or subcutaneous) administration. The vaccine is most preferably injected intramuscularly into the deltoid muscle. The vaccine is preferably combined with a pharmaceutically acceptable carrier to facilitate administration. The carrier is usually water or a buffered saline, with or without a preservative. The vaccine may be lyophilized for re-suspension at the time of administration or in solution.

The carrier to which the paralogues, antibody or derived blocking peptides may be conjugated may also be a polymeric delayed release system. Synthetic polymers are particularly useful in the formulation of a vaccine to effect the controlled release of antibody. Microencapsulation of the paralogues, antibody or derived blocking peptide will also give a controlled release. A number of factors contribute to the selection of a particular polymer for microencapsulation. The reproducibility of polymer synthesis and the microencapsulation process, the cost of the microencapsulation materials and process, the toxicological profile, the requirements for variable release kinetics and the physicochemical compatibility of the polymer and the antigens are all factors that must be considered. Examples of useful polymers are

polycarbonates, polyesters, polyurethanes, polyorthoesters polyamides, poly (d,l-lactide-co-glycolide) (PLGA) and other biodegradable polymers.

5 The preferred dose for human administration of the pharmaceutical composition or vaccine is from 0.01 mg/kg to 10 mg/kg. Based on this range, equivalent dosages for heavier body weights can be determined. The dose should be adjusted to suit the individual to whom the composition is administered and will vary with age, weight and metabolism of the individual. The vaccine may additionally contain stabilizers such as thimerosal (ethyl(2-mercaptobenzoate-S)mercury sodium salt) (Sigma Chemical Company, St. Louis, MO) or
10 physiologically acceptable preservatives.

Region II DNA vaccines were constructed using the DNA vaccine backbone VR1020 for the panel of EBPs using standard molecular biological methods. EBP Region II gene inserts were
15 amplified by PCR and verified by restriction enzyme mapping and DNA sequencing of the complete insert (*ebp2* and *ebp3*) or plasmid junctions (*ebp4* and *ebp5*).

Polyclonal anti-sera from groups of Balb/c immunized by DNA vaccination were tested for recognition of *Plasmodium falciparum*
20 blood stage proteins by indirect immunofluorescence antibody test (IFAT) using methanol fixed parasitized erythrocytes.

VM92 cells were transiently transfected with the panel of EBP Region II DNA vaccines as described for EBP2 and culture supernatants were tested for secreted EBP Region II protein by
25 immunoblot using homologous DNA vaccinated mouse antiserum.

TABLE 1 is a summary of EBP2, EBP3, EBP4, and EBP5 region II DNA vaccine construction, expression *in vitro* and generation of polyclonal anti-EBP2, EBP3, EBP4, and EBP5 antisera *in vivo*.

TABLE 1

Protein identifier	Gene identifier	Chromosome location	EBP Region RII DNA vaccine produced	Mice immunized	IFAT staining results	Immunoblot results
BBA-175 or SABP ¹	<i>eba-175</i> (or <i>ebp1</i>)	7	Yes	Yes	Positive	Positive
EBP2	<i>ebp2</i>	13	Yes	Yes	Positive	Positive
EBP3	<i>ebp3</i>	13	Yes	Yes	Negative	Negative
EBP4	<i>ebp4</i>	4	Yes	Yes	Negative	Negative
EBP5	<i>ebp5</i>	1	Yes	Yes	Negative	Negative

5 The paralogues and antibodies of the present invention
 may also be used for the detection of *P. falciparum* peptides in biological
 samples or culture media. There are many techniques known in the art for
 detecting a component such as a polypeptide in a mixture and/or
 measuring its amount. Immunoassays, which employ antibodies that bind
 specifically to the polypeptide of interest, are one of the better known
 10 measurement techniques. Classical methods involve reacting a sample
 containing the polypeptide with a known excess amount of antibody
 specific for the polypeptide, separating bound from free antibody, and
 determining the amount of one or the other. Often the antibody is labeled
 with a reporter group to aid in the determination of the amount of bound
 15 analyte as described above. The reporter group or "label" is commonly a
 fluorescent or radioactive group or an enzyme.

 An immunoassay is performed for the detection of *P.*
 falciparum in a sample as follows:

20 A sample is collected or obtained using methods well
 known to those skilled in the art. The sample containing the *P.*
 falciparum polypeptides to be detected may be obtained from an culture
 media or any biological source. Examples of biological sources include
 blood serum, blood plasma, urine, spinal fluid, fermentation fluid, lymph
 fluid, tissue culture fluid and ascites fluid. The sample may be diluted,

purified, concentrated, filtered, dissolved, suspended or otherwise manipulated prior to immunoassay to optimize the immunoassay results.

To detect *P. falciparum* polypeptides, the sample is incubated with one or more of the *P. falciparum* erythrocyte binding protein paralogue antibodies of the present invention. The antibody may be labeled or conjugated to a solid phase bead or particle as also described herein. The labeled antibody is then detected using methods well known to those skilled in the art. The term "detecting" or "detected" as used herein means using known techniques for detection of biologic molecules such as immunochemical or histological methods. Such methods include immunological techniques employing monoclonal or polyclonal antibodies to the peptides, such as enzyme linked immunosorbant assays, radioimmunoassay, chemiluminescent assays, or other types of assays involving antibodies known to those skilled in the art.

Current binding assay technology benefits from the diversity of detection systems developed that use enzyme-catalyzed chromogenic reactions, radionuclides, chemiluminescence, bioluminescence, fluorescence, fluorescence polarization and a variety of potentiometric and optical biosensor techniques.

Binding assays rely on the binding of analyte by analyte receptors to determine the concentrations of analyte in a sample. Analyte-receptor assays can be described as either competitive or non-competitive. Non-competitive assays generally utilize analyte receptors in substantial excess over the concentration of analyte to be determined in the assay. Sandwich assays are examples of non-competitive assays, that comprise one analyte receptor frequently bound to a solid phase and a second analyte receptor labeled to permit detection. The analyte first binds to the analyte receptor bound to a solid phase and the second labeled analyte receptor is then added to facilitate quantitation of the analyte. Bound analyte can easily be separated from unbound reagents, such as unbound labeled first analyte receptors, due to the use of an analyte receptor bound to a solid phase.

Competitive assays generally involve a sample suspected of containing analyte, an analyte-analogue conjugate, and the competition of these species for a limited number of binding sites provided by the analyte receptor. Competitive assays can be further described as being either homogeneous or heterogeneous. In homogeneous assays all of the reactants participating in the competition are mixed together and the quantity of analyte is determined by its effect on the extent of binding between analyte receptor and analyte-conjugate or analyte analogue-conjugate. The signal observed is modulated by the extent of this binding and can be related to the amount of analyte in the sample. U.S. Patent No. 3,817,837 describes such a homogeneous, competitive assay in which the analyte analogue conjugate is a analyte analogue-enzyme conjugate and the analyte receptor, in this case a paralogue of EBA-175 or an antibody thereof, is capable of binding to either the analyte or the analyte analogue. The binding of the paralogue or antibody to the analyte analogue-enzyme conjugate decreases the activity of the enzyme relative to the activity observed when the enzyme is in the unbound state. Due to competition between unbound analyte and analyte analogue-enzyme conjugate for analyte-receptor binding sites, as the analyte concentration increases the amount of unbound analyte analogue-enzyme conjugate increases and thereby increases the observed signal. The product of the enzyme reaction may then be measured kinetically using a spectrophotometer.

Heterogeneous, competitive assays require a separation of analyte analogue conjugate bound to analyte receptor from the free analyte analogue conjugate and measurements of either the bound or the free fractions. Separation of the bound from the free may be accomplished by removal of the analyte receptor and anything bound to it from the free analyte analogue conjugate by immobilization of the analyte receptor on a solid phase or precipitation. The amount of the analyte analogue conjugate in the bound or the free fraction can then be determined and related to the concentration of the analyte in the sample. Normally the bound fraction is in a convenient form, for example, on a solid phase, so that it can be washed, if necessary, to remove remaining

unbound analyte analogue conjugate and the measurement of the bound analyte analogue conjugate or related products is facilitated. The free fraction is normally in a liquid form that is generally inconvenient for measurements. If multiple analytes are being determined in a single assay, the determination of the free fraction of analyte analogue conjugate for each analyte is made impossible if all are mixed in a single liquid unless the responses of the individual analyte analogue conjugates can be distinguished in some manner. However, detecting the free fraction of analyte analogue conjugate in assays that are visually interpreted is a distinct advantage because the density of the color developed in such assays is generally proportional to the analyte concentration over much of the range of analyte concentration.

In a preferred embodiment, the method for detecting and characterizing *P. falciparum* polypeptides comprises taking a sample from a protein production lot. A determination of the presence of the immunodominant polypeptides can then be made using assay techniques that are well known to those skilled in the art and include methods such as Western blot analysis, radioimmunoassay and ELISA assays.

In a second preferred embodiment, the method for detecting *P. falciparum* polypeptides comprises taking biological samples, such as fluids and tissues, from a mammal for the diagnosis or prognosis of malaria. The sample is preferably obtained from the blood, cerebrospinal fluid, urine or tissues of a mammal, preferably a human or simian. A determination of the presence of the immunodominant polypeptides can then be made using assay techniques that are well known to those skilled in the art and include methods such as Western blot analysis, radioimmunoassay and ELISA assays.

A kit for detecting the presence and quantity of *P. falciparum* paralogues, antibodies thereof and/or derived peptides is also provided. The kit can be in any configuration well known to those of ordinary skill in the art and is useful performing one or more of the methods described herein for the detection of *P. falciparum* in biological samples or for the detection or monitoring of *P. falciparum* infection in a

patient or carrier. The kits are convenient in that they supply many if not all of the essential reagents for conducting an assay for the detection of *P. falciparum* in a biological sample. The reagents may be premeasured and contained in a stable form in vessels or on a solid phase in or on which the assay may be performed, thereby minimizing the number of manipulations carried out by the individual conducting the assay. In addition, the assay may be performed simultaneously with a standard that is included with the kit, such as a predetermined amount of a paralogue of the invention, or antigen or antibody thereof, so that the results of the test can be validated or measured.

In one embodiment, the kit preferably contains one or more *Plasmodium falciparum* erythrocyte binding protein antibodies that can be used for the detection of *P. falciparum* binding proteins in a sample. The kit can additionally contain the appropriate reagents for binding or hybridizing the antibodies to their respective *P. falciparum* binding molecules or ligands in the sample as described herein and reagents that aid in detecting the bound peptides. The kit may additionally contain equipment for safely obtaining the sample, a vessel for containing the reagents, a timing means, a buffer for diluting the sample, and a colorimeter, reflectometer, or standard against which a color change may be measured.

In another preferred embodiment, the reagents, including the antibody, are lyophilized, most preferably in a single vessel. Addition of aqueous sample to the vessel results in solubilization of the lyophilized reagents, causing them to react. Most preferably, the reagents are sequentially lyophilized in a single container, in accordance with methods well known to those skilled in the art that minimize reaction by the reagents prior to addition of the sample.

The assay kit includes but is not limited to reagents to be employed in the following techniques; competitive and non-competitive assays, radioimmunoassay, bioluminescence and chemiluminescence assays, fluorometric assays, sandwich assays, immunoradiometric assays, dot blots, enzyme linked assays including immunoblots and ELISAs, and

immunocytochemistry. Materials used in conjunction with these techniques include, but are not limited to, microtiter plates, antibody coated strips or dipsticks for rapid monitoring of urine or blood. For each kit, the range, sensitivity, precision, reliability, specificity and reproducibility of the assay are established. Intraassay and interassay variation is established at 20%, 50% and 80% points on the standard curves of displacement or activity.

In a further preferred embodiment, the assay kit uses immunoblot techniques and provides instructions, *P. falciparum* polypeptides, and *P. falciparum* erythrocyte binding protein antibodies conjugated to a detectable molecule. The kit is useful for the measurement of *P. falciparum* in biological fluids and tissue extracts of animals and humans with and without malaria, as well as in culture media.

This invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention and/or the scope of the appended claims. All patents and references disclosed herein are incorporated by reference.

EXAMPLE 1

Materials and methods for detecting P. falciparum EBPs

Genomic Database

The sequence data for *P. falciparum* chromosome 13 was obtained from The Sanger Centre website at http://www.sanger.ac.uk/Projects/P_falciparum/. Sequencing of *P.*

falciparum chromosome 13 was accomplished as part of the Malaria Genome Project with support by The Wellcome Trust.

Parasites

5 *Plasmodium falciparum* 3D7 strain (clone of NF54, Amsterdam Airport, human challenge strain) and FVO strain (Aotus adapted) were maintained as previously reported (Vernes et al., 1984). When appropriate, schizonts were purified on Percoll density gradient. The 3D7 parasites were metabolically labeled with TRAN³⁵S-LABEL™
10 (ICN Radiochemicals, Irvine, CA) as previously described (Sim *et al.*, 1994b). Essentially 2 x 10⁸ parasites in 10 ml RPMI-1640 culture media deficient in methionine and cysteine were incubated with 1 mCi TRAN³⁵S-LABEL™ for 4 hours for parasite-cell pellets and 16-24 hours for culture supernatants. Parasitized erythrocytes for preparation of
15 schizont extracts were washed twice in RPMI-1640 and cell pellets were frozen at -70°C. For the collection of labeled parasite proteins, cells were removed by centrifugation (1 min. at 20,000 x g) and supernatants were stored at -70°C.

20 RT-PCR analysis

 Aliquots of purified mRNA, isolated from purified schizont infected erythrocytes using a mRNA isolation kit (Stratagene, La Jolla, CA), were stored precipitated in ethanol with 3M sodium acetate at -70°C. The mRNA was treated with DNAase to ensure that it was free of
25 genomic DNA; the absence of DNA was confirmed by the lack of amplification in RT-PCR studies in the absence of reverse transcriptase. First strand cDNA transcripts were prepared using a poly dT primer from a cDNA CYCLE™ kit (Invitrogen, Carlsbad, CA). This first strand product was amplified by PCR using the oligonucleotide forward primer
30 5' CAAGGAGAATGTATGGAAAGTA 3' and reverse primer 5' ATCTTCATATTCATTTGGACTCT 3'. The PCR amplified product was detected by ethidium bromide staining a 1% agarose gel.

EBP2 DNA sequence analysis and plasmid vaccine construction

P. falciparum EBP2 RII (amino acids 147-762, 1848bp) was amplified using AdvanTaq Plus™ DNA polymerase (Clontech, Palo Alto, CA) from 100 ng of 3D7 genomic DNA using the forward primer 5'ATGCGGATCCCAATATACGTTTATACAGAAACGTACTC 3' and reverse primer 5'ATGCGGATCCTCATATATCGTGTTTTGTTTTAGG 3' which both contained a BamHI site and the reverse primer contained an additional internal stop codon for cloning into the shuttle vector PCR-Script™ as described by the manufacturer's instructions (Stratagene, La Jolla, CA). The *ebp2* RII gene fragment excised with BamHI and cloned into the expression plasmid vector VR1020 (identified as pEBP2-RII). The VR1020 plasmid vector utilizes the human cytomegalovirus promoter and intron A, and human tissue plasminogen activator as the secretory signal and the bovine growth hormone transcriptional terminator/polyadenylation signal (Hartikka *et al.*, 1996). A clone was selected for correct orientation by restriction-enzyme mapping. Both the forward and reverse strands of the *ebp2* RII ORF were sequenced using primers off of the vector and primers based on the cloned sequences (Veritas, Inc., Rockville, MD). Human melanoma cells (UM449), were transiently transfected with the plasmids pEBP2RII, 3D7 encoded pEBA-175RII and VR1020 plasmid with Lipofectamine™ following the manufacture's protocol (Life Technologies, Gaithersburg, MD). Secretion of RII protein in culture supernatants was confirmed by Western blot. Plasmids were prepared for immunizations using an EndoFree Plasmid Giga kit (Qiagen, Valencia, CA). Purity was gauged by UV spectroscopy (260nm/280nm was between 1.70 and 1.90), agarose gel electrophoresis showing predominately supercoiled plasmid and endotoxin levels (<10 EU/mg) were detected using the *Limulus* *amebocyte* assay. The *ebp2* RVI was amplified by PCR as above except used Vent DNA polymerase (New England BioLabs, Beverly, MA) using the forward primer 5' TCTAGAGATACTAAAAGAGTAAGG 3' and reverse primer 5' TGATTGACCCTCGCTTTTAAAAC 3'. The PCR

amplified fragment was gel purified and both the forward and reverse strands were sequenced directly (Veritas, Inc.).

Animals and immunizations

5 All animal studies were done in compliance with protocols approved by Animal Care and Use Committees. BALB/c mice were inoculated intradermally with a 29 gauge needle at two sites in the tail with a total of 50 µg VR1020 (empty vector), pEBP2RII in 50 µl PBS. The mice were inoculated on days 0, 21, 42 and bled approximately two weeks after each immunization. A fourth dose was administered approximately three months after the third dose and bled two weeks later. Pooled sera were assessed for antibodies to parasitized erythrocytes by IFA.

Immunoprecipitation, immunoblotting and immunofluorescence assay

15 Aliquots of approximately 2×10^8 parasitized RBCs that had been metabolically labeled were extracted in buffer containing 1% Triton X-100 (Sigma, St. Louis, MO) (Narum *et al.*, 1994). Schizont infected erythrocyte lysates (50 to 75 µl) were immunoprecipitated with mouse serum or purified rabbit IgG coupled to Protein G (Pharmacia Biotech., Uppsala, Sweden) and the precipitates were washed as previously described using a buffer containing Triton X-100 (Deans and Jeans, 1987; Narum *et al.*, 1994). The labeled proteins were resolved by SDS-PAGE and detected and/or quantified with a phosphorimager (BioRad Molecular Imager FX, Hercules, CA). Immunoblots were prepared essentially as described previously (Narum *et al.*) using EBP specific antisera. IFA on thin films containing schizont-infected erythrocytes used mouse anti-EBP2 sera (1/50 dilution in PBS-1%FCS) and rabbit anti-EBA-175 RII IgG (2 µg/ml in buffer) were co-incubated for 1 hour in a moisture chamber. After washing in PBS, the parasitized cells were co-incubated with species specific fluorescein or Alexa™ 546 labeled secondary antibodies (Kirkegaard & Perry Laboratories, Inc.,

Gaithersburg, MD and Molecular Probes, Eugene, OR, respectively). The same microscope field was photographed using excitation for both fluorescein and Alexa 546. Alexa 546 emission appears orange.

5 EBPs binding studies and blocking of binding to erythrocytes

Metabolically labeled parasite culture supernatant containing [³⁵S]-metabolically labeled EBPs was used for erythrocyte binding assays as previously described by Camus and Hadley (1985) or Sim *et al.* (1994). Briefly, two samples were prepared containing 1 ml
10 [³⁵S]-labeled culture supernatant and 2 x 10⁹ packed erythrocytes that were incubated for 45 minutes at room temperature while rocking for binding to occur. To one vial, the erythrocytes were pelleted, washed thrice in PBS and the erythrocyte pellet was extracted in 500 µl 1% Triton X-100 extraction buffer. EBP bound erythrocyte lysates were
15 immunoprecipitated using 80 µl extract with antigen specific antisera or control sera coupled to Protein G. The other sample was divided into four parts and the EBPs were eluted from erythrocytes with 9 µl of RPMI 1640, 1.5 M NaCl, 10% FCS, and 2 mM phenylmethylsulfonyl fluoride as previously described (Sim *et al.*, 1994). Elution material was pooled and
20 diluted 15-fold in PBS-1%FCS and equal volumes were immunoprecipitated with antigen specific antisera or control sera as above. Gels were dried and quantified with a phosphorimager (BioRad Molecular Imager FX, Hercules, CA).

Blocking of binding was performed by pre-incubating a
25 titration of EBP2 specific antisera with 100 µl [³⁵S]-labeled culture supernatant for 45 minutes and then 2 x 10⁸ erythrocytes were added and incubated for 30 minutes at room temperature while rocking. Erythrocyte pellets were washed thrice with PBS, extracted in 50 µl 1% Triton X-100 extraction buffer, immunoprecipitated with EBP2 antisera coupled to
30 Protein G and analyzed as above. Blocking of binding was calculated as follows: (control – experiment/control) x 100. The “control” is the counts from EBP2 bound to erythrocytes in the presence of control sera.

Neuraminidase treatment of erythrocytes:

Human blood was collected in a final 10% citrate phosphate dextrose solution, washed and treated with 0.2 U per 1×10^9 erythrocytes *Vibrio cholerae* neuraminidase (Gibco BRL, Gaithersburg, MD) as previously described (Liang et al 2000).

EXAMPLE 2

Expression of EBP2 in parasitized erythrocytes

To examine whether *ebp2* was transcribed a mRNA transcript was detected with RT-PCR. Parasite mRNA isolated from 3D7 schizont-infected erythrocytes was used for first strand synthesis with random primers or with a poly dT primer and then PCR amplified with an *ebp2* primer pair or *eba-175* primer pair as a control. Appropriate size DNA fragments were detected on an ethidium bromide stained agarose gel for *ebp2* and *eba-175*. Using genomic 3D7 DNA, *ebp2* RII was amplified by PCR and cloned into a naked DNA vaccine plasmid (Hartikka *et al.*, 1996). Both the forward and reverse strands of the DNA fragment were sequenced. A single point nucleotide change at position 1654 (A to G) encoded an amino acid substitution from Asn to Asp. This single amino acid difference is the result of a PCR-introduced artifact.

Recombinant EBP2 RII and EBA-175 RII derived from supernatants by transient transfection of UM449 cells were immunoblotted with specific antisera generated as below. A western blot of secreted *P. falciparum* 3D7 EBP2 RII (A) and 3D7 EBA-175 RII (B) proteins showed expression of EBP2 *in vitro* and specificity of EBP2 and EBA-175 antibodies. UM449 cells were transiently transfected with naked DNA plasmid pEBP2 RII and run in lane 1. VR1020 (Vical, San Diego, CA) control was run in lane 2. pEBA-175 RII was run in lane 3. EBP2 RII and EBA-175 RII recombinant proteins were detected by RII specific mouse antibodies. EBP2 RII and EBA-175 RII anti-sera were specific for self and showed no detectable cross-reactivity.

Pooled immune sera from BALB/c mice immunized with the EBP2 RII DNA vaccine and empty vector as control were tested for the presence of EBP2 RII specific antibodies by Immunofluorescence assay (IFA). The IFA showed co-localization of EBP2 and EBA-175 within *P. falciparum* schizont infected erythrocyte. EBP2 was stained with mouse anti-EBP2 RII sera and EBA-175 was stained with rabbit anti-EBA-175 RII IgG. Both primary and secondary antibody controls were negative for staining. Cells were magnified 1000-fold. EBP2 RII antisera recognized 3D7 and FVO schizont-infected erythrocytes and gave a punctate apical pattern of fluorescence. The reciprocal end-point titer of pooled immune sera was 1600 on 3D7 parasitized erythrocytes by IFA. The subcellular pattern of apical fluorescence was compared to EBA-175 using EBA-175 RII specific antibodies generated in rabbits. The results showed that EBP2 and EBA-175 colocalized to the same subcellular location within the merozoite's apex.

EXAMPLE 3

EBP2 RII specific antibodies recognize a 130 kDa P. falciparum protein

To determine the molecular mass of EBP2 [³⁵S]-metabolically labeled *P. falciparum* 3D7 strain schizont-infected erythrocyte lysates were incubated with EBP2 RII specific antibodies coupled to Protein G-sepharose. [³⁵S]-labeled *P. falciparum* schizont-infected erythrocyte lysate were immunoprecipitated and human erythrocyte bound [³⁵S]-labeled EBP2 were detected from [³⁵S]-labeled parasite culture supernatants. EBA-175 specific polyclonal rabbit IgG was included as a control. Results were obtained with EBP2 specific polyclonal sera or control and EBA-175 specific polyclonal IgG and control. [³⁵S]-labeled EBP2 and EBA-175 were immunoprecipitated from lysates of erythrocytes with bound EBPs. [³⁵S]-labeled EBP2 and EBA-175 were eluted off human erythrocytes with 1M NaCl and then immunoprecipitated with EBP2 or EBA-175 specific antibodies. Mouse

and rabbit adjuvant controls and molecular mass markers were employed. The molecular mass of processed or degraded forms of EBP2 were: a, 117.2; b, 92.2; c, 85.8; and d, 69.7 kDa. EBP2 RII antibodies immunoprecipitated a 130 kDa molecule as determined by SDS-PAGE under reducing conditions. The theoretical molecular mass of the *ebp2* ORF is 133,018 Daltons hence the observed molecular mass is similar to the theoretical. EBA-175 was also immunoprecipitated with EBA-175 RII specific rabbit polyclonal IgG as a control. The EBP2 RII antisera did not immunoprecipitate the abundantly labeled EBA-175 nor did EBA-175 RII antibodies immunoprecipitate EBP2.

EXAMPLE 4

EBP2 binds human erythrocytes

It was determined that EBP2 bound to human erythrocytes by using [³⁵S]-labeled *P. falciparum* culture supernatants that contained *P. falciparum* proteins released during maturation of schizogony *in vitro*. Immunoprecipitation of human erythrocyte lysates or eluates prepared as described in Materials and Methods showed that EBP2 bound human erythrocytes. EBA-175 specific rabbit IgG and rabbit control IgG were included in the analysis. The binding affinity of EBP2 was greater than that of EBA-175. Immunoprecipitation of erythrocyte lysates that were prepared by incubating erythrocytes and [³⁵S]-labeled *P. falciparum* culture supernatants, washed with PBS and incubated with mouse EBP2 RII and rabbit EBA-175 RII specific antibodies showed that EBP2 was not removed by the PBS while EBA-175 was removed. EBP2 RII antisera predominately immunoprecipitated a 69.7 kDa fragment although other larger fragments were also detected but were only weakly visible. The 69.7 kDa fragment identified in the culture supernatant appears to be a processed or degraded product of the larger 130 kDa form of EBP2 identified in schizont-infected erythrocyte lysates. Analysis of erythrocyte eluates obtained by immunoprecipitation showed similar binding patterns for EBP2, although the intensity of the other fragments by this approach

was greater. The EBP2 fragments were 117.2, 92.2, 85.8 and 69.7 kDa. EBA-175 was detected using these conditions as previously reported (Orlandi *et al.*, 1990).

5

EXAMPLE 5

EBP2 RII specific antibodies block EBP2 erythrocyte binding

To determine whether EBP RII antibodies blocked EBP2 binding to erythrocytes, EBP2 immune sera was titrated with [³⁵S]-labeled *P. falciparum* culture supernatants, which was then incubated with human erythrocytes, pelleted, washed and extracted in extraction buffer. Control antisera was at a single dilution of 1/10. Equal volumes of erythrocyte lysate were immunoprecipitated with EBP2 specific polyclonal antibodies. Immunoprecipitation of the erythrocyte lysates demonstrated that EBP2 RII specific antibodies blocked EBP2 binding to human erythrocytes (Figure 6). The ED₅₀ blocking titer was between 1/160 and 1/640.

10

15

EXAMPLE 6

EBP2 binding to human erythrocytes is dependent on sialic acid residues

Human erythrocytes were used in untreated form or were enzymatically treated with neuraminidase, which cleaves sialic acid residues. The erythrocytes were then incubated with [³⁵S]-labeled *P. falciparum* culture supernatants. Red blood cells (RBCs) were pelleted, washed and extracted in extraction buffer. Equal volumes of erythrocyte lysate were immunoprecipitated with EBP2 specific polyclonal antibodies. EBP2 bound the untreated erythrocytes. Human erythrocytes devoid of sialic acid residues (i.e., neuraminidase treated erythrocytes) did not bind the 69.7 kDa fragment of EBP2. The sialic acid binding results were similar when we tested for EBP2 binding using an EBA-175 erythrocyte binding assay.

25

30

EXAMPLE 7

Preparation of vaccines using EBP3

DNA vaccine that encoded region II of EBP3 was constructed similarly to EBP2 region II. Forward primer for EBP3: 5' ATGC GGA TCC GAA AAG AAT AAA TTT ATT GAC ACT 3' BamHI; Reverse primer for EBP3: 5' ATGC GGA TCC TCA AGG AAA CAC ATT CGT TTT TAT AGG 3' BamHI. Mice were immunized and polyclonal immune sera were tested for recognition of parasite proteins by IFAT on methanol fixed parasitized erythrocytes. The results are shown in the Table 1 above. The IFAT results were all negative for detection of an expressed parasite protein except for the novel protein EBP2. EBA-175 was used as a positive control in these studies. EBP3 polyclonal immune was also tested by immunoblot against supernatant collected from VM92 cells transiently transfected individually with the EBP DNA vaccine. The results were all negative except for EBP2 for self-recognition of a transiently expressed region II fragment of EBP2. Although the results for EBP3 was negative here, these studies do not exclude the expression of this protein in erythrocytic stage parasites or in other parasite stages e.g., sporozoite, exo-erythrocytic, or sexual stage parasites.

EXAMPLE 8

Preparation of vaccines using EBP4

DNA vaccine that encoded region II of EBP4 was constructed by directly cloning EBP4 into the DNA vaccine VR1020. Specific forward and reverse primers with BamHI restriction sites were used to PCR amplify from genomic (*P. falciparum*) DNA (Fig. 2) using standard molecular biological techniques that are known in the art. Forward primer for EBP4: 5' ATGC GGA TCC AAT CTG AAA GCT CCA AAT GCT AAA TCC 3' BamHI; Reverse primer for EBP4: 5' ATGC GGA TCC TCA TAT AGG AAA CAC ATT CGT TTT TAT

AGG 3' BamHI. Mice were immunized and polyclonal immune sera were tested for recognition of parasite proteins by IFAT on methanol fixed parasitized erythrocytes. The results are shown in the Table 1 above. The IFAT results were all negative for detection of an expressed parasite protein except for the novel protein EBP2. EBA-175 was used as a positive control in these studies. EBP4 polyclonal immune was also tested by immunoblot against supernatant collected from VM92 cells transiently transfected individually with the EBP DNA vaccine. The results were all negative except for EBP2 for self-recognition of a transiently expressed region II fragment of EBP4. Although the results for EBP4 was negative here, these studies do not exclude the expression of this protein in erythrocytic stage parasites or in other parasite stages such as sporozoite, exo-erythrocytic, or sexual stage parasites.

15

EXAMPLE 9

Preparation of vaccines using EPB5

DNA vaccine that encoded region II of EBP5 was constructed by directly cloning EBP5 into the DNA vaccine VR1020. Specific forward and reverse primers with BamHI restriction sites were used to PCR amplify from genomic (*P. falciparum*) DNA (Fig. 2) using standard molecular biological techniques that are known in the art. Forward primer for EBP5: 5' ATGC GGA TCC AAT AGA AAT AGT TTT GTT CAA 3' BamHI; Reverse primer for EBP5: 5' ATGC GGA TCC TCA TGA GTC TAT AGA TAA CAT TTC 3' BamHI. Mice were immunized and polyclonal immune sera were tested for recognition of parasite proteins by IFAT on methanol fixed parasitized erythrocytes. The results are shown in the Table 1 above. The IFAT results were all negative for detection of an expressed parasite protein except for the novel protein EBP2. EBA-175 was used as a positive control in these studies. EBP5 polyclonal immune was also tested by immunoblot against supernatant collected from VM92 cells transiently transfected individually with the EBP DNA vaccine. The results were all negative except for

EBP2 for self-recognition of a transiently expressed region II fragment of EBP2. Although the results for EBP5 was negative here, these studies do not exclude the expression of this protein in erythrocytic stage parasites or in other parasite stages such as sporozoite, exo-erythrocytic, or sexual stage parasites.

Modifications and variations of the present method will be obvious to those skilled in the art from the foregoing detailed description. Such modifications and variations are intended to come within the scope of the appended claims. All patents, patent applications and publications cited in this application are herein incorporated by reference as if each were incorporated individually.

References

- Adams, J. H., Hudson, D. E., Torii, M., Ward, G. E., Wellems, T. E., Aikawa, M., Miller, L. H. "The Duffy receptor family of *Plasmodium knowlesi* is located within the micronemes of invasive malaria merozoites." *Cell*. 63: 141-153 (1990).
- Adams, J.H., Sim, B.K.L., Dolan, S.A., Fang, X., Kaslow, D.C., Miller, L.H. "A family of erythrocyte binding proteins of malaria parasites." *Proc. Natl. Acad. Sci.* 89: 7085-7089 (1992).
- Camus, D., and T.J. Hadley. A *Plasmodium falciparum* antigen that binds to host erythrocytes and merozoites. *Science*. 1985; 230, no. 4725:553.
- Deans, J. A., and W. C. Jeans. 1987. Structural studies on a putative protective *Plasmodium knowlesi* merozoite antigen. *Molecular Biochemical Parasitology*. 26:155-166.
- Dolan, S. A., J. L. Proctor, D. W. Alling, Y. Okubo, T. E. Wellems, and L. H. Miller. 1994. Glycophorin B as an EBA-175 independent

Plasmodium falciparum receptor of human erythrocytes. *Mol Biochem Parasitol.* 64:55-63.

5 Fang, X., Kaslow, D. C., Adams, J. H., Miller, L. H. "Cloning of the *Plasmodium vivax* Duffy receptor." *Mol. Biochem. Parasitol.* 44: 125-132 (1991).

10 Hartikka, J., M. Sawdey, F. Cornefert-Jensen, M. Margalith, K. Barnhart, M. Nolasco, H. L. Vahlsing, J. Meek, M. Marquet, P. Hobart, J. Norman, and M. Manthorpe. 1996. An improved plasmid DNA expression vector for direct injection into skeletal muscle. *Hum Gene Ther.* 7:1205-17.

15 Horuk, R., C. E. Chitnis, W. C. Darbonne, T. J. Colby, A. Rybicki, T. J. Hadley, and L. H. Miller. 1993. A receptor for the malarial parasite *Plasmodium vivax*: the erythrocyte chemokine receptor. *Science.* 261:1182-4.

20 Narum, D. L., and A. W. Thomas. 1994. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of *Plasmodium falciparum* merozoites. *Mol Biochem Parasitol.* 67:59-68.

25 Narum, D. L., J. D. Haynes, S. Fuhrmann, K. Moch, H. Liang, S. L. Hoffman, and B. K. Sim. 2000. Antibodies against the plasmodium *falciparum* receptor binding domain of EBA-175 block invasion pathways that Do not involve sialic acids [In Process Citation]. *Infect Immun.* 68:1964-6.

30 Orlandi, P. A., B. K. Sim, J. D. Chulay, and J. D. Haynes. 1990. Characterization of the 175-kilodalton erythrocyte binding antigen of *Plasmodium falciparum*. *Mol Biochem Parasitol.* 40:285-94.

Orlandi, P.A., Klotz, F. W. and Haynes, J.D. "A malaria invasion receptor, the 175-kilodalton erythrocyte binding antigen of *Plasmodium*

falciparum recognizes the terminal neu5Ac(α 2-3)gal-sequences of glycophorin A." *J. Cell Biol.* 116: 901-909 (1992).

5 Sim, B.K., P.A. Orlandi, J.D. Haynes, F.W. Klotz, J.M. Carter, D. Camus, M.E. Zegans, and J.D. Chulay. Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. *J Cell Biol.* 1990; 111, no. 5 Pt 1:1877-1884.

10

Sim, B. K., T. Toyoshima, J. D. Haynes, and M. Aikawa. 1992. Localization of the 175-kilodalton erythrocyte binding antigen in micronemes of Plasmodium falciparum merozoites. *Mol Biochem Parasitol.* 51:157-9.

15

Sim, B. K. L., Chitnis, C.E., Wasniowska, K., Hadley, T.J., Miller, L.H. "Receptor and ligand domains for invasion of erythrocytes by *Plasmodium falciparum*. *Science.* 264:1941-1944. (1994).

20

What is claimed is:

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated polypeptide comprising a paralogue of EBA-175 polypeptide sequence.
2. The pharmaceutical composition of Claim 1, wherein the paralogue of EBA-175 polypeptide sequence is encoded by the sequence of SEQ ID NO:1.
3. The pharmaceutical composition of Claim 1, further comprising an isolated sialic acid binding protein (SABP) binding domain polypeptide in an amount sufficient to induce a protective immune response to *Plasmodium falciparum* merozoites in a mammal.
4. An isolated polypeptide comprising a paralogue of EBA-175 polypeptide sequence.
5. The isolated polypeptide of Claim 4, wherein the paralogue of EBA-175 polypeptide sequence is encoded by the sequence of SEQ ID NO:1.
6. An isolated nucleic acid sequence comprising a paralogue of EBA-175 nucleic acid sequence.
7. The isolated nucleic acid sequence of Claim 6, wherein the paralogue of EBA-175 nucleic acid sequence comprises the sequence of SEQ ID NO:1.
8. A vector comprising a paralogue of EBA-175 nucleic acid sequence.
9. The vector of Claim 8, wherein the paralogue of EBA-175 nucleic acid sequence comprises the sequence of SEQ ID NO:1.
10. A recombinant host cell comprising a paralogue of EBA-175 nucleic acid sequence.

11. The recombinant host cell of Claim 10, wherein the
paralogue of EBA-175 nucleic acid sequence comprises the sequence of
SEQ ID NO:1.

5

12. A recombinant host cell comprising the vector of claim 8.

10

13. A method for an immune response to *Plasmodium falciparum* merozoites in a patient, the method comprising administration to the patient of an immunologically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated polypeptide comprising a paralogue of EBA-175 polypeptide sequence.

15

14. The method of Claim 13, wherein the paralogue of EBA-175 polypeptide sequence is encoded by the sequence of SEQ ID NO:1.

20

15. The method of claim 14, further comprising administration to the patient of an immunologically effective amount of an isolated SABP binding domain polypeptide.

25

16. A recombinant method for making a paralogue of EBA-175 polypeptide, comprising:
expressing the vector of claim 8 in a host cell; and
isolating the paralogue of EBA-175 polypeptide from said host cell.

30

17. An isolated antibody, wherein the antibody binds a 5' cysteine rich region of an EBA-175 protein paralogue from a *Plasmodium* species.

35

18. The isolated antibody of Claim 17, wherein the 5' cysteine rich region is a region II.

19. The isolated antibody of Claim 18, wherein the 5' cysteine rich region is a region II/F2.

20. The isolated antibody of Claim 17, wherein the antibody inhibits binding of an EBA-175 protein to a red blood cell.




Fig. 1

Majority	- N - - - - M K G X - N I Y F L X X X I I L Y - V - R - - - - I S R X E Y - -	
	10 20 30 40	
EBP1.SEQ	- - - - - M K C N I S I Y F P A S F F V L Y P A K - - - - A R N E Y D I	79
EBP2.SEQ	T N K L Y I M K G Y F N I Y F L I P L I F L Y N V I R I N E S I T G R T L Y N R	118
EBP3.SEQ	- - - - - K C F - - - F F L S K S I I - - - - R N K D V D I S I K D F - -	67
EBP4.SEQ	W N - - - - M K G K M N M C L F F F Y S I L Y V V L C T Y V L G I S - E E Y - L	4
EBP5.SEQ	N N - - - - M K G K M N M C L F F F Y S I L Y V V L C T Y V L G I S - E E Y - L	100
Majority	K E X X K G L D V Y X - N - - - N N N - - - - D - - - F - - - - N K L	
	50 60 70 80	
EBP1.SEQ	K E N E K F L D V Y K E K F N E L D K K K Y G N V Q K T D K K I F T F I E N K L	199
EBP2.SEQ	Q D E S S - - D I S R V N S P B L N N N H K T N I Y D S D - - - Y E D V N N K L	223
EBP3.SEQ	- E K N K F I D T Y S -	97
EBP4.SEQ	- - - - - G L -	10
EBP5.SEQ	K E R P Q G L N V E T N N N N - - - - N N N N N N N S N S N D A M S F V - - - N E V	205
Majority	- - - - - N - K - - K - - - - - - - - - - D K X X X I I - - - - - F	
	90 100 110 120	
EBP1.SEQ	- D I L N N S K F N K R W K S Y G T P D N I D K N M S L I N K H N N - - E E M F	310
EBP2.SEQ	I N S F V E N K S V K K K R S L S F I N N K T K S Y D I I P P S Y S Y R N D K F	343
EBP3.SEQ	- -	97
EBP4.SEQ	- -	25
EBP5.SEQ	I R F I E N E K D D K E - - - - - - - - - - D K K V K I I S R P V E N T L H R Y	295
Majority	N - - - - S - L - I S X Y G - - N - Y - N - N - - - - - S F - Q - R	
	130 140 150 160	
EBP1.SEQ	N N N Y Q S F L S T S S L I K Q N K Y V P I N A V R V S R - - - I L S F L D S R	421
EBP2.SEQ	N S L S E N - E D N S G N T N S N N F A N T S E I S I G K D N K Q Y T F I Q K R	460
EBP3.SEQ	- -	97
EBP4.SEQ	- -	40
EBP5.SEQ	P - - - V S S F L N I K K Y G R K G E Y L N R N - - - - - S F V Q R S	376
Majority	- - - - - L - - - - - C G X K R K X I K W I C X X N X X K S N N V C I	
	170 180 190 200	
EBP1.SEQ	I N N G R N T S S N N E V L S N C R E K R K G M K W D C K K K N D R S N Y V C I	541
EBP2.SEQ	T H - - - - - L F A C G I K R K S I K W I C R E N S E K I T - V C V	544
EBP3.SEQ	- - - - - L Y E C G K K I K E M K W I C T D N Q F K S N N L C A	178
EBP4.SEQ	- -	55
EBP5.SEQ	Y I R G - - - - - C K G K R S T H T W I C E N K G N - - - N N I C I	454
Majority	P D R R I Q L C I V N L X X X K X T X E - - - - - - - - - - K L K D N V L E A	
	210 220 230 240	
EBP1.SEQ	P D R R I Q L C I V N L S I I K T Y T K E - - - - - - - - - - T M K D H F I E A	631
EBP2.SEQ	P D R I Q L C I A N F L N S R L E T M E - - - - - - - - - - K F K E I F L I S	634
EBP3.SEQ	P I R R I Q L C I V N I I L F S E N E N E Y I Y K N D S I N N K F K E N I L K A	298
EBP4.SEQ	- -	79
EBP5.SEQ	P D R R V Q L C I T A L Q D L K N S G S E - - - - - T D R K L L R D K V F D S	559
Majority	V K X E S X L L X N K N X N K Y N S K F C D D L K N S F L D Y G D I I I G X D L	
	250 260 270 280	
EBP1.SEQ	S K K E S Q L L L K K N D N K Y N S K F C N D L K N S F L D Y G H L A M G N D M	751
EBP2.SEQ	V N T E A K L L Y N K N R G K D P S I F C N E L R N S F S D F R N S F I G D D M	754
EBP3.SEQ	V K L E S N L L V Q K H N N E Y N S K L C D D I R W S F L D Y G D I I I G R D L	418
EBP4.SEQ	- -	100
EBP5.SEQ	A M Y E T D L L W N K Y G F R G F D D F C D D V K N S Y L D Y K D V I F G T D L	679

Fig. 2A

Fig. 2B

Majority	X D G - - - - N L E X L K E H I L X A A I Y E G K L L K E K Y K N K - - - -																																									
	570										580										590										600											
EBP1.SEQ	Y	D	K	-	-	-	-	N	L	L	M	I	K	E	H	I	L	A	I	A	I	Y	E	S	R	I	L	K	R	K	Y	K	N	K	-	-	-	-	1600			
EBP2.SEQ	H	R	G	-	-	-	-	H	E	E	D	Y	K	E	H	L	L	G	A	S	I	Y	E	A	Q	L	L	K	Y	K	Y	K	E	K	-	-	-	-	1594			
EBP3.SEQ	R	D	G	-	-	-	-	N	E	E	G	L	K	D	H	I	N	K	A	A	N	Y	E	A	M	H	L	K	E	K	Y	E	N	A	-	-	-	-	1282			
EBP4.SEQ	K	D	E	F	K	N	V	N	D	L	K	K	F	L	N	E	I	I	L	G	I	R	D	E	G	K	F	L	I	E	K	Y	R	K	N	M	H	E	N	M	643	
EBP5.SEQ	N	D	D	I	Y	N	V	H	N	-	S	Q	L	I	E	I	I	M	A	S	K	Q	E	G	K	L	L	W	K	K	-	-	-	-	H	G	T	I	1531			
Majority	- D D X X A C K I I N X S Y A D I K D I I X G X D X W N D X N S I K L E E N L N																																									
	610										620										630										640											
EBP1.SEQ	-	D	D	K	E	V	C	K	I	I	N	K	T	F	A	D	I	R	D	I	I	G	G	T	D	Y	W	N	D	L	S	N	R	K	L	V	G	K	I	N	1717	
EBP2.SEQ	-	D	E	N	A	L	C	S	I	I	Q	N	S	Y	A	D	L	A	D	I	I	K	G	S	D	I	I	K	D	Y	Y	G	K	K	M	E	E	N	L	N	1711	
EBP3.SEQ	-	G	G	D	K	I	C	N	A	I	L	G	S	Y	A	D	I	G	D	I	V	R	G	L	D	V	W	R	D	I	N	T	N	K	L	S	B	K	F	Q	1399	
EBP4.SEQ	Y	L	D	E	R	A	C	K	Y	L	N	Y	S	F	D	D	Y	K	N	I	I	L	G	K	D	M	W	R	D	P	N	S	I	K	T	E	N	I	L	K	763	
EBP5.SEQ	L	D	N	Q	N	A	C	K	Y	I	N	D	S	Y	V	D	Y	K	D	I	V	I	G	N	D	L	W	N	D	N	N	S	I	K	V	Q	N	N	L	N	1651	
Majority	K I F E X N X G X R N K Q - - - - - S L K E F R N K W W D X N K N X V																																									
	650										660										670										680											
EBP1.SEQ	T	N	-	-	S	N	Y	V	H	R	N	K	Q	-	-	-	-	-	-	-	-	-	-	N	D	K	L	F	R	D	E	W	W	K	V	I	K	K	D	V	1801	
EBP2.SEQ	K	V	-	-	N	K	D	K	K	R	N	E	E	-	-	-	-	-	-	-	-	-	-	S	L	K	I	F	R	E	K	W	W	D	E	N	K	E	N	V	1795	
EBP3.SEQ	K	I	F	M	G	G	N	S	R	K	K	Q	-	-	-	-	-	-	-	-	-	-	-	N	D	N	N	E	R	N	K	W	W	E	K	Q	R	N	L	I	1489	
EBP4.SEQ	G	N	F	E	-	-	G	I	K	A	N	I	V	S	M	Y	P	S	Y	A	D	L	S	L	D	E	F	R	K	H	W	W	D	Q	N	K	K	Q	L	874		
EBP5.SEQ	L	I	F	E	R	N	F	G	Y	K	V	G	R	N	K	L	F	K	T	-	-	-	-	I	K	E	L	K	N	V	W	W	I	L	N	R	N	K	V	1756		
Majority	W E V M S C V I - - - - X K K K T C K R X D D F E N I P Q F L R W F S E W G D D																																									
	690										700										710										720											
EBP1.SEQ	W	N	V	I	S	W	V	F	-	-	-	K	D	K	T	V	C	K	E	-	D	D	I	E	N	I	P	Q	F	F	R	W	F	S	E	W	G	D	D	1906		
EBP2.SEQ	W	K	V	M	S	A	V	L	-	-	-	K	N	K	E	T	C	K	D	Y	D	K	F	Q	K	I	P	Q	F	L	R	W	F	K	E	W	G	D	D	1903		
EBP3.SEQ	W	S	S	M	V	K	H	I	-	-	-	P	K	G	K	T	C	K	R	H	N	N	F	E	K	I	P	Q	F	L	R	W	L	K	E	W	G	D	E	1597		
EBP4.SEQ	W	E	A	I	S	C	E	F	Y	K	G	N	H	T	-	G	V	C	L	M	E	D	D	N	D	N	-	-	Q	Y	L	H	W	F	R	E	W	K	N	D	985	
EBP5.SEQ	W	E	S	M	R	C	G	I	D	E	V	D	Q	R	R	K	T	C	E	R	I	D	E	L	E	N	M	P	Q	F	F	R	W	F	S	Q	W	A	H	F	1876	
Majority	F C E D K X - - - - - K E I C X X E K X K V E C K X K N C S D - - X X C K N K																																									
	730										740										750										760											
EBP1.SEQ	Y	C	Q	D	K	T	-	-	-	-	K	M	I	-	-	E	T	L	K	V	E	C	K	E	K	P	C	E	D	-	-	D	N	C	K	R	K	1993				
EBP2.SEQ	F	C	E	K	R	K	-	-	-	-	E	K	I	Y	S	F	E	S	F	K	V	E	C	K	K	D	C	D	E	-	-	N	T	C	K	N	K	1999				
EBP3.SEQ	F	C	E	E	M	G	-	-	-	-	T	E	V	K	Q	L	E	K	I	-	-	-	C	E	N	K	N	C	S	E	-	-	K	K	C	K	N	A	1684			
EBP4.SEQ	F	C	I	D	K	L	K	W	N	D	V	I	K	E	P	C	I	D	K	K	V	K	S	P	K	P	S	E	N	P	S	D	V	A	T	V	C	N	K	S	1105	
EBP5.SEQ	F	C	K	E	K	E	Y	W	E	L	K	L	N	D	K	C	T	G	N	N	G	K	S	L	C	Q	D	K	T	-	-	-	-	-	C	Q	N	V	1975			
Majority	C S S Y K K W I X X K K X E Y E K Q S K K Y D K D K K L F N N Y - - Y - E F K D																																									
	770										780										790										800											
EBP1.SEQ	C	N	S	Y	K	E	W	I	S	K	K	E	E	Y	N	K	Q	A	K	Q	Y	Q	E	Y	Q	K	-	G	N	N	Y	K	M	Y	S	E	F	K	S	2110		
EBP2.SEQ	C	S	E	Y	K	K	W	I	D	L	K	K	S	E	Y	E	K	Q	V	D	K	Y	T	K	D	K	N	-	K	K	M	Y	D	N	I	D	E	V	K	N	2116	
EBP3.SEQ	C	S	S	Y	E	K	W	I	K	E	R	K	N	E	Y	N	L	Q	S	K	K	F	D	S	D	K	K	L	N	K	K	N	N	L	Y	N	K	F	E	D	1804	
EBP4.SEQ	C	T	D	Y	D	K	W	I	I	N	K	R	K	E	Y	K	M	Q	S	S	K	Y	K	R	D	R	S	L	F	N	N	V	-	-	-	I	Q	N	1210			
EBP5.SEQ	C	T	N	M	N	Y	W	T	Y	T	R	K	L	A	Y	E	I	Q	S	V	K	Y	D	K	D	R	K	L	F	S	-	L	-	-	-	A	K	D	2077			
Majority	K K A X V Y L K E X S K K C S N I N F X D E I F X E L P N X Y K E X C T - C X -																																									
	810										820										830										840											
EBP1.SEQ	I	K	P	E	V	Y	L	K	K	Y	S	E	K	C	S	N	L	N	F	E	D	E	F	K	E	E	L	H	S	D	Y	K	N	K	C	T	M	C	P	-	2227	
EBP2.SEQ	K	E	A	N	V	Y	L	K	E	K	S	K	E	C	K	D	V	N	F	D	D	K	I	F	N	E	S	P	N	E	Y	E	D	M	C	K	K	C	D	-	2233	
EBP3.SEQ	S	K	A	-	-	Y	L	R	S	-	-	S	K	Q	C	S	N	I	E	F	N	D	E	T	F	T	-	F	P	N	K	Y	K	E	A	C	M	V	C	E	-	1912
EBP4.SEQ	L	K	P	W	E	Y	L	-	-	-	S	M	K	C	T	E	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	C	T	-	C	N	L	1264
EBP5.SEQ	K	N	V	T	T	F	L	K	E	N	A	K	N	C	S	N	I	D	F	T	-	K	I	F	D	Q	L	D	K	L	F	K	E	R	C	S	-	C	-	M	2188	

Fig. 2C

Fig. 2D

Fig. 2E

Majority	R X D X T L L T X D X R X T - L E - - - R N G - - N I - S E S D V X - H X F H X																																								
	1410										1420										1430										1440										
EBP1.SEQ	R	N	S	N	T	L	H	L	K	D	I	R	N	E	E	N	R	H	L	T	N	Q	N	I	N	I	S	Q	E	R	D	L	Q	K	H	G	F	H	T	3799	
EBP2.SEQ	R	G	D	T	T	S	N	T	H	D	V	R	R	T	-	-	-	-	-	-	-	-	-	-	-	N	I	V	S	E	R	R	V	N	S	H	D	F	-	I	2962
EBP3.SEQ	S	T	D	Y	E	S	L	T	E	E	S	P	K	G	D	L	E	S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3112
EBP4.SEQ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2479
EBP5.SEQ	L	I	D	I	H	L	L	R	N	E	A	G	S	T	I	L	D	D	S	R	R	N	G	S	M	T	E	G	S	E	S	D	V	G	E	L	Q	E	H	N	3982
Majority	X S N X X G D E X X - - - I - - - - - G - I Q - - X - - - - E E S G N V L N M																																								
	1450										1460										1470										1480										
EBP1.SEQ	M	N	N	L	H	G	D	G	V	S	E	R	S	Q	I	N	H	S	H	H	G	N	R	Q	D	R	G	-	-	-	G	N	S	G	N	V	L	N	M	3907	
EBP2.SEQ	R	N	G	M	A	N	N	N	A	H	H	Q	Y	I	T	Q	I	E	N	N	G	I	I	R	G	Q	E	-	-	-	E	S	A	G	N	S	V	N	-	3067	
EBP3.SEQ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3142
EBP4.SEQ	I	S	N	I	E	G	G	E	E	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2536
EBP5.SEQ	F	S	T	Q	Q	K	D	E	K	D	F	D	Q	I	A	S	D	R	E	K	E	I	Q	K	L	L	N	I	G	H	E	E	D	E	D	V	L	K	M	4102	
Majority	X R N - - S X X D N P N S X N Y - - - D - K - N I E E Y N N R D X S K V R E L																																								
	1490										1500										1510										1520										
EBP1.SEQ	R	S	N	N	N	N	F	N	N	I	P	S	R	Y	N	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4018
EBP2.SEQ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3169
EBP3.SEQ	K	P	N	K	S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3208
EBP4.SEQ	P	R	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2623
EBP5.SEQ	D	R	T	E	D	S	M	S	D	G	V	N	S	H	L	Y	Y	N	N	L	S	S	E	E	K	M	E	Q	Y	N	N	R	D	A	S	K	D	R	E	4222	
Majority	I X K L S K X N K C X N E X S X K Y C X Y M X X E X - L L X T C S X E K R K X L																																								
	1530										1540										1550										1560										
EBP1.SEQ	I	K	K	L	A	E	I	N	K	C	E	N	E	I	S	V	K	Y	C	D	H	M	I	H	E	E	I	P	L	K	T	C	T	K	E	K	T	R	N	L	4138
EBP2.SEQ	I	I	K	L	S	K	Q	N	K	C	N	N	E	Y	S	M	E	Y	C	T	Y	S	D	E	R	N	S	S	P	G	P	C	S	R	E	E	R	K	L	3289	
EBP3.SEQ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3208
EBP4.SEQ	I	M	R	S	Y	K	S	N	R	C	T	N	N	L	S	S	N	Y	C	S	K	L	K	K	E	S	-	L	S	N	T	C	T	N	E	D	S	K	R	L	2740
EBP5.SEQ	I	L	N	R	S	N	T	N	T	C	S	N	E	H	S	L	K	Y	C	Q	Y	M	E	R	N	K	D	L	L	E	T	C	S	E	D	K	R	L	H	L	4342
Majority	C C X I S D Y C L K F F N F X S I E Y Y N C T K K E F D S P X Y K C F R G E G F																																								
	1570										1580										1590										1600										
EBP1.SEQ	C	C	A	V	S	D	Y	C	M	S	Y	F	T	Y	D	S	E	R	Y	Y	N	C	T	K	R	E	F	D	D	P	S	Y	T	C	F	R	K	E	A	-	4255
EBP2.SEQ	C	C	Q	I	S	D	Y	C	L	K	Y	F	N	F	Y	S	I	E	Y	Y	N	C	I	K	S	E	I	K	S	P	E	Y	K	C	F	K	S	E	G	Q	3409
EBP3.SEQ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3253
EBP4.SEQ	C	C	S	I	S	D	Y	C	M	K	F	F	N	F	N	S	S	G	Y	H	S	C	M	R	K	E	F	S	N	H	A	Y	K	C	F	A	G	K	G	F	2860
EBP5.SEQ	C	C	E	I	S	D	Y	C	L	K	F	F	N	P	K	S	I	E	Y	F	D	C	T	Q	K	E	F	D	D	P	T	Y	N	C	F	R	K	Q	R	F	4462
Majority	S S M F X - - - - -																																								
	1610																																								
EBP1.SEQ	-	-	-	-	F	S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4261
EBP2.SEQ	S	S	M	F	H	I	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3427
EBP3.SEQ	S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3256	
EBP4.SEQ	S	S	M	F	N	L	D	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	K	2914	
EBP5.SEQ	T	S	M	S	C	Y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4501	

Decoration 'Decoration #1': Box residues that match the Consensus exactly.

Fig. 2F




Fig. 3

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.